1.Megalocytic Interstitial Nephritis Following Acute Pyelonephritis with Escherichia coli Bacteremia: A Case Report.
Hee Jin KWON ; Kwai Han YOO ; In Young KIM ; Seulkee LEE ; Hye Ryoun JANG ; Ghee Young KWON
Journal of Korean Medical Science 2015;30(1):110-114
Megalocytic interstitial nephritis is a rare form of kidney disease caused by chronic inflammation. We report a case of megalocytic interstitial nephritis occurring in a 45-yrold woman who presented with oliguric acute kidney injury and acute pyelonephritis accompanied by Escherichia coli bacteremia. Her renal function was not recovered despite adequate duration of susceptible antibiotic treatment, accompanied by negative conversion of bacteremia and bacteriuria. Kidney biopsy revealed an infiltration of numerous histiocytes without Michaelis-Gutmann bodies. The patient's renal function was markedly improved after short-term treatment with high-dose steroid.
Acute Disease
;
Acute Kidney Injury/complications/*drug therapy/pathology
;
Anti-Bacterial Agents/therapeutic use
;
Azithromycin/therapeutic use
;
Bacteremia/*drug therapy/microbiology/pathology
;
Cefotaxime/therapeutic use
;
Creatinine/blood
;
Escherichia coli
;
Escherichia coli Infections/*drug therapy/microbiology/pathology
;
Female
;
Humans
;
Kidney/pathology
;
Methylprednisolone/therapeutic use
;
Middle Aged
;
Nephritis, Interstitial/*drug therapy/immunology/pathology
;
Pyelonephritis/complications/*drug therapy/pathology
;
Renal Dialysis
;
Shock, Septic/drug therapy/microbiology
2.A Case of Late Onset-Acute Tubulointerstitial Nephritis with Infliximab and Mesalazine Treatment in a Patient with Crohn's Disease.
Yang Jae YOO ; Sang Yoon CHUNG ; Dae Hoe GU ; Gang Jee KO ; Heui Jung PYO ; Young Joo KWON ; Young Tae BAK ; Nam Hee WON
The Korean Journal of Gastroenterology 2014;63(5):308-312
Infliximab is a chimeric anti-tumor necrosis factor-alpha monoclonal antibody. Infusion related reactions and infection are well known side effects of infliximab; however, renal complications have not been well recognized. We report on a patient with late onset-acute tubulointerstitial nephritis (ATIN) after treatment with infliximab and mesalazine for Crohn's disease. A 25-year-old woman was admitted with a purpuric rash on both lower extremities and arthralgia. She had been diagnosed with Crohn's disease 5.6 years previously and had been treated with mesalazine and infliximab. Serum creatinine level, last measured one year ago, was elevated from 0.6 mg/dL to 1.9 mg/dL. Results of urinalysis, ultrasound, and serologic examinations were normal. With a tentative diagnosis of Henoch-Schonlein purpura, oral prednisolone was given, and serum creatinine decreased to 1.46 mg/dL, but was elevated to 2.6 mg/dL again at two months after discontinuation of prednisolone. Renal biopsy indicated that ATIN was probably induced by drug, considering significant infiltration of eosinophils. Concomitant use of infliximab with mesalazine was supposed to trigger ATIN. Oral prednisolone was administered, and serum creatinine level showed partial recovery. Thus, ATIN should be suspected as a cause of renal impairment in Crohn's disease even after a long period of maintenance treatment with infliximab and mesalazine.
Adalimumab/therapeutic use
;
Anti-Inflammatory Agents/therapeutic use
;
Creatine/blood
;
Crohn Disease/*drug therapy
;
Drug Therapy, Combination
;
Eosinophils/immunology
;
Female
;
Humans
;
Infliximab/*adverse effects/*therapeutic use
;
Kidney/pathology
;
Mesalamine/*adverse effects/*therapeutic use
;
Nephritis, Interstitial/*diagnosis/drug therapy/*etiology
;
Prednisolone/therapeutic use